It’s an excellent interview to watch. DW again points out that it’s the surgeons who are leading the way with new opportunities for using the Novosorb tech, and not just BTM. But I do like his focus on at present going all out for the “low hanging fruit” of BTM use in the US.
As for the shorters, they are his “friends” because at some point they are going to have to cover approx 60 million shares. I get the feeling that he thinks that this might occur before PNV drops from the index. But if it doesn’t the business will still continue to make progress and eventually the game will have been played out.
David Williams on Talk Ya Book with Chris Judd, page-3
-
- There are more pages in this discussion • 137 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.34 |
Change
-0.030(1.27%) |
Mkt cap ! $1.616B | |||
| Open | High | Low | Value | Volume |
| $2.41 | $2.43 | $2.32 | $5.953M | 2.536M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 29039 | $2.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.35 | 16702 | 3 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |